Evaxion Expands Preclinical Bacterial Vaccine Pipeline In Collaboration With Leading Pharmaceutical Company
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech A/S (NASDAQ:EVAX) has announced a collaboration with an undisclosed pharmaceutical company to expand its preclinical bacterial vaccine pipeline. The project, EVX-B3, will use Evaxion's proprietary AI platforms, EDEN™ and RAVEN™, to design a novel vaccine candidate for a bacterial pathogen with high medical need and no current vaccine. The project is co-funded by both companies.
September 18, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evaxion's collaboration with a leading pharmaceutical company to develop a novel vaccine could potentially boost its stock in the short term. The use of AI in vaccine development could also position Evaxion as a leader in the field.
The news of a collaboration with a leading pharmaceutical company for the development of a novel vaccine is likely to be seen positively by investors. Additionally, the use of AI in vaccine development could be seen as innovative and potentially game-changing, which could further boost investor confidence in Evaxion.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100